Gilead Sciences, Inc. $GILD Position Raised by Putney Financial Group LLC

Putney Financial Group LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 53.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 270 shares of the biopharmaceutical company’s stock after acquiring an additional 94 shares during the quarter. Putney Financial Group LLC’s holdings in Gilead Sciences were worth $30,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Simon Quick Advisors LLC lifted its position in Gilead Sciences by 210.1% in the 2nd quarter. Simon Quick Advisors LLC now owns 27,392 shares of the biopharmaceutical company’s stock valued at $3,037,000 after purchasing an additional 18,558 shares during the last quarter. Strs Ohio increased its stake in shares of Gilead Sciences by 4.3% in the second quarter. Strs Ohio now owns 534,303 shares of the biopharmaceutical company’s stock valued at $59,238,000 after purchasing an additional 22,123 shares during the period. Impact Partnership Wealth LLC raised its holdings in shares of Gilead Sciences by 66.2% during the second quarter. Impact Partnership Wealth LLC now owns 13,138 shares of the biopharmaceutical company’s stock valued at $1,457,000 after buying an additional 5,232 shares during the last quarter. Amalgamated Bank boosted its position in shares of Gilead Sciences by 9.2% during the second quarter. Amalgamated Bank now owns 270,927 shares of the biopharmaceutical company’s stock worth $30,038,000 after buying an additional 22,916 shares during the period. Finally, Atria Investments Inc boosted its position in shares of Gilead Sciences by 22.3% during the second quarter. Atria Investments Inc now owns 79,026 shares of the biopharmaceutical company’s stock worth $8,762,000 after buying an additional 14,392 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $118.44 on Friday. Gilead Sciences, Inc. has a 52 week low of $86.08 and a 52 week high of $124.61. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a market cap of $146.96 billion, a PE ratio of 23.59, a price-to-earnings-growth ratio of 0.81 and a beta of 0.34. The company’s 50-day moving average price is $115.56 and its two-hundred day moving average price is $111.48.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter in the previous year, the company posted $2.02 EPS. The business’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Citigroup increased their target price on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday, October 8th. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a research report on Monday, October 20th. Finally, The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $105.00 to $108.00 and gave the stock a “neutral” rating in a research note on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $122.61.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the sale, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at $69,389,826.17. This trade represents a 1.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $354,240.00. Following the completion of the transaction, the insider owned 110,193 shares in the company, valued at $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 71,500 shares of company stock worth $8,336,040. Insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.